Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linsitinib - Sling Therapeutics

Drug Profile

Linsitinib - Sling Therapeutics

Alternative Names: ASP-7487; Linsitinib - Astellas Pharma; OSI-906; OSI-906AA

Latest Information Update: 05 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OSI Pharmaceuticals
  • Developer Astellas Pharma; Multiple Myeloma Research Foundation; Sling Therapeutics
  • Class Cyclobutanes; Imidazoles; Pyrazines; Quinolines; Small molecules
  • Mechanism of Action Insulin receptor antagonists; Insulin-like growth factor-I receptor antagonists; Protein tyrosine kinase inhibitors; Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenocortical carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Graves ophthalmopathy
  • Preclinical Autoimmune disorders; Unspecified
  • Discontinued Adrenocortical carcinoma; Liver cancer; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 01 Jul 2022 Phase-II clinical trials in Graves ophthalmopathy in USA (PO) (NCT05276063) (Sling Therapeutics pipeline, June 2022)
  • 29 Jun 2022 Linsitinib - Sling Therapeutics is available for licensing as of 29 Jun 2022. https://live-vasaragen.pantheonsite.io/pipeline/
  • 29 Jun 2022 Preclinical trials in Autoimmune disorders in USA (PO) in June 2022 (Sling Therapeutics pipeline, June 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top